TY - JOUR
T1 - Pathways to therapy resistance
T2 - The sheltering effect of the bone marrow microenvironment to multiple myeloma cells
AU - Bhowmick, Kuntal
AU - von Suskil, Max
AU - Al-Odat, Omar S.
AU - Elbezanti, Weam Othman
AU - Jonnalagadda, Subash C.
AU - Budak-Alpdogan, Tulin
AU - Pandey, Manoj K.
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/6/30
Y1 - 2024/6/30
N2 - Multiple Myeloma (MM) is a malignant expansion of plasma cells in the bone marrow (BM), resulting in a disease characterized by symptoms of end organ damage from light chain secretion, crowding of the BM, and bone lesions. Although the past two decades have been characterized by numerous novel therapies emerging, the disease remains incurable due to intrinsic or acquired drug resistance. A major player in MM's drug resistance arises from its intimate relationship with the BM microenvironment (BMME). Through stress-inducing conditions, soluble messengers, and physical adhesion to BM elements, the BMME activates numerous pathways in the myeloma cell. This not only propagates myeloma progression through survival and growth signals, but also specific mechanisms to circumvent therapeutic actions. In this review, we provide an overview of the BMME, the role of individual components in MM survival, and various therapy-specific resistance mechanisms reported in the literature.
AB - Multiple Myeloma (MM) is a malignant expansion of plasma cells in the bone marrow (BM), resulting in a disease characterized by symptoms of end organ damage from light chain secretion, crowding of the BM, and bone lesions. Although the past two decades have been characterized by numerous novel therapies emerging, the disease remains incurable due to intrinsic or acquired drug resistance. A major player in MM's drug resistance arises from its intimate relationship with the BM microenvironment (BMME). Through stress-inducing conditions, soluble messengers, and physical adhesion to BM elements, the BMME activates numerous pathways in the myeloma cell. This not only propagates myeloma progression through survival and growth signals, but also specific mechanisms to circumvent therapeutic actions. In this review, we provide an overview of the BMME, the role of individual components in MM survival, and various therapy-specific resistance mechanisms reported in the literature.
UR - http://www.scopus.com/inward/record.url?scp=85196301149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85196301149&partnerID=8YFLogxK
U2 - 10.1016/j.heliyon.2024.e33091
DO - 10.1016/j.heliyon.2024.e33091
M3 - Review article
AN - SCOPUS:85196301149
SN - 2405-8440
VL - 10
JO - Heliyon
JF - Heliyon
IS - 12
M1 - e33091
ER -